

## CORRECTION



# Correction: Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide

Junhong Li , Zhe Hong , Junyu Zhang, Shengfeng Zheng, Fangning Wan, Zheng Liu and Bo Dai

© The Author(s), under exclusive licence to Springer Nature Limited 2026


*Oncogene* (2026) 45:805–807; <https://doi.org/10.1038/s41388-026-03690-3>

Correction to: *Oncogene* <https://doi.org/10.1038/s41388-024-02945-1>, published online 19 January 2024

Upon recent review of figures in this paper, the authors identified an overlap in certain areas of Figure 2d pertaining to the migration assay of C4-2 cells in the transwell experiment for the shSMYD2#1 and shSMYD2#2 groups. Upon re-examining the original data, they found that an image from the shSMYD2#1 condition was inadvertently mislabeled as shSMYD2#2-1 during archiving. This occurred as a filing error when handling the multiple images captured for each sample group. Owing to the minor overlap, this mistake was unfortunately not caught during multiple rounds of proofreading. The authos apologize for this oversight. This was unintentional clerical error, and does not affect the scientific conclusions of the study.

The original article has been corrected.

Original Fig 2d:



Corrected Fig 2d:

